Skip to main content
Erschienen in: Endocrine 3/2019

29.12.2018 | Original Article

18F-choline PET/CT incidental thyroid uptake in patients studied for prostate cancer

verfasst von: Domenico Albano, Rexhep Durmo, Francesco Bertagna, Raffaele Giubbini

Erschienen in: Endocrine | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Thyroid incidental uptake is defined as a thyroid uptake incidentally detected by imaging examinations performed for non-thyroid disease. The aim of this study was to establish the prevalence and the pathological nature of focal thyroid incidental uptake (FTIU) among patients studied with 18F-choline-PET/CT.

Materials and methods

We retrospectively evaluated 368 patients who performed 18F-choline-PET/CT between June 2016 and August 2018. The PET images were analyzed visually and semi-quantitatively by measuring the maximum standardized uptake value (SUVmax) and the mean SUV (SUVmean) of the thyroid gland and of the FTIU; every focal thyroid uptake deviating from physiological distribution and background was considered FTIU. Final diagnosis of FTIU was obtained by cytological or histological examination after surgery.

Results

The average SUVmax and SUVmean of thyroid gland in population were 3 and 1.8. Among 368 patients, FTIU was identified in nine cases (2.4%) and eight underwent further investigations to determine the nature. Two FTIU were classified as malignant (thyroid carcinoma), whereas five were benign (three nodular hyperplasia, one follicular adenoma, one Hurtle cell adenoma) and one indeterminate at cytological examination. In malignant lesions, average SUVmax was 9.6 and 4.5, respectively, while average SUVmean was 5.3 and 2.9, respectively. Average SUVmax and SUVmean of benign lesions were 4.9 and 3.2 and of the indeterminate lesion 5 and 3, respectively.

Conclusions

18F-choline-PET/CT FTIU may be a relevant diagnostic reality, which requires further investigations and affects management, especially considering that, despite being mainly benign, also malignancy is possible.
Literatur
1.
Zurück zum Zitat B. Burguera, H. Gharib, Thyroid incidentalomas. Prevalence, diagnosis, significance, and management. Endocrinol. Metab. Clin. N. Am. 29, 187–203 (2000)CrossRef B. Burguera, H. Gharib, Thyroid incidentalomas. Prevalence, diagnosis, significance, and management. Endocrinol. Metab. Clin. N. Am. 29, 187–203 (2000)CrossRef
2.
Zurück zum Zitat N.G. Iyer, A.R. Shaha, C.E. Silver, K.O. Devaney, A. Rinaldo, P.K. Pellitteri et al. Thyroid incidentalomas: to treat or not to treat. Eur. Arch. Otorhinolaryngol. 267, 1019–1026 (2010)CrossRefPubMed N.G. Iyer, A.R. Shaha, C.E. Silver, K.O. Devaney, A. Rinaldo, P.K. Pellitteri et al. Thyroid incidentalomas: to treat or not to treat. Eur. Arch. Otorhinolaryngol. 267, 1019–1026 (2010)CrossRefPubMed
3.
Zurück zum Zitat A. Tamburello, G. Treglia, D. Albano, F. Bertagna, L. Giovanella, Prevalence and clinical significance of focal incidental 18F-FDG uptake in different organs: an evidence-based summary. Clin. Transl. Imaging 5, 525 (2017)CrossRef A. Tamburello, G. Treglia, D. Albano, F. Bertagna, L. Giovanella, Prevalence and clinical significance of focal incidental 18F-FDG uptake in different organs: an evidence-based summary. Clin. Transl. Imaging 5, 525 (2017)CrossRef
4.
Zurück zum Zitat M. Salvatori, L. Melis, P. Castaldi, M.L. Maussier, V. Rufini, G. Perotti et al. Clinical significance of focal and diffuse thyroid diseases identified by (18)F-fluorodeoxyglucose positron emission tomography. Biomed. Pharmacother. 61, 488–493 (2007)CrossRefPubMed M. Salvatori, L. Melis, P. Castaldi, M.L. Maussier, V. Rufini, G. Perotti et al. Clinical significance of focal and diffuse thyroid diseases identified by (18)F-fluorodeoxyglucose positron emission tomography. Biomed. Pharmacother. 61, 488–493 (2007)CrossRefPubMed
5.
Zurück zum Zitat H.B. Wu, Q.S. Wang, M.F. Wang, H.S. Li, Utility of 11C-choline imaging as a supplement to F-18 FDG PET imaging for detection of thyroid carcinoma. Clin. Nucl. Med. 36, 91–95 (2011)CrossRefPubMed H.B. Wu, Q.S. Wang, M.F. Wang, H.S. Li, Utility of 11C-choline imaging as a supplement to F-18 FDG PET imaging for detection of thyroid carcinoma. Clin. Nucl. Med. 36, 91–95 (2011)CrossRefPubMed
6.
Zurück zum Zitat A. Eccles, A. Challapalli, S. Khan, T. Barwick, S. Mangar, Thyroid lymphoma incidentally detected by 18F-fluorocholine (FCH) PET/CT. Clin. Nucl. Med. 38, 755–757 (2013)CrossRefPubMed A. Eccles, A. Challapalli, S. Khan, T. Barwick, S. Mangar, Thyroid lymphoma incidentally detected by 18F-fluorocholine (FCH) PET/CT. Clin. Nucl. Med. 38, 755–757 (2013)CrossRefPubMed
7.
Zurück zum Zitat G. Paone, G. Treglia, M. Bongiovanni, T. Roberto, L. Ceriani, L. Giovanella, Incidental detection of Hurtle cell adenoma by 18F-choline PET/CT scan in a patient with prostate cancer. Rev. Esp. Med Nucl. Imagen Mol. 32, 340–341 (2013)PubMed G. Paone, G. Treglia, M. Bongiovanni, T. Roberto, L. Ceriani, L. Giovanella, Incidental detection of Hurtle cell adenoma by 18F-choline PET/CT scan in a patient with prostate cancer. Rev. Esp. Med Nucl. Imagen Mol. 32, 340–341 (2013)PubMed
8.
Zurück zum Zitat G. Treglia, E. Giovannini, P. Mirk, D. Di Franco, L. Oragano, F. Bertagna, A thyroid incidentaloma detected by 18F-choline PET/CT. Clin. Nucl. Med. 39, e267–e269 (2014)CrossRefPubMed G. Treglia, E. Giovannini, P. Mirk, D. Di Franco, L. Oragano, F. Bertagna, A thyroid incidentaloma detected by 18F-choline PET/CT. Clin. Nucl. Med. 39, e267–e269 (2014)CrossRefPubMed
9.
Zurück zum Zitat M. Hodolic, V. Huchet, S. Balogova, L. Michaud, K. Kerrou, V. Nataf et al. Incidental uptake of 18F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. Radiol. Oncol. 48, 228–234 (2014)CrossRefPubMedPubMedCentral M. Hodolic, V. Huchet, S. Balogova, L. Michaud, K. Kerrou, V. Nataf et al. Incidental uptake of 18F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. Radiol. Oncol. 48, 228–234 (2014)CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat A.L. Aziz, F. Courbon, L.O. Diericks, P. Pascal, S. Zerdoud, Oncocytic adenoma of thyroid incidentally detected by 18F-fluorocholine PET/CT. J. Nucl. Med. Technol. 43, 133–134 (2015)CrossRefPubMed A.L. Aziz, F. Courbon, L.O. Diericks, P. Pascal, S. Zerdoud, Oncocytic adenoma of thyroid incidentally detected by 18F-fluorocholine PET/CT. J. Nucl. Med. Technol. 43, 133–134 (2015)CrossRefPubMed
11.
Zurück zum Zitat A.M. Garcia Vicente, A. Nunez Garcia, A.M. Soriano Castrejon, G.A. Jimenez Londono, J.M. Cordero Garcia, A. Palomar Munoz, Pitfalls with 18F-choline PET/CT in patients with prostate cancer. Rev. Esp. Med Nucl. Imagen Mol. 32, 37–39 (2013)PubMed A.M. Garcia Vicente, A. Nunez Garcia, A.M. Soriano Castrejon, G.A. Jimenez Londono, J.M. Cordero Garcia, A. Palomar Munoz, Pitfalls with 18F-choline PET/CT in patients with prostate cancer. Rev. Esp. Med Nucl. Imagen Mol. 32, 37–39 (2013)PubMed
12.
Zurück zum Zitat P. Lalire, M. Zalzali, C. Garbar, C. Bruna-Muraille, D. Morland, Incidental detection of oxifilic papillary thyroid carcinoma by 18F-fluorocholine PET/CT. Clin. Nucl. Med. 41, 512–513 (2016)CrossRefPubMed P. Lalire, M. Zalzali, C. Garbar, C. Bruna-Muraille, D. Morland, Incidental detection of oxifilic papillary thyroid carcinoma by 18F-fluorocholine PET/CT. Clin. Nucl. Med. 41, 512–513 (2016)CrossRefPubMed
13.
Zurück zum Zitat A. Outtara, T. Ribeiro de Oliveira, S. Holz, H. Van den Bossche, D. Strybol, C. Assenmacher et al. Incidental detection of occult thyroid carcinoma with 11C-choline PET/CT for high risk prostate cancer. Curr. Urol. 10, 217–220 (2016)CrossRef A. Outtara, T. Ribeiro de Oliveira, S. Holz, H. Van den Bossche, D. Strybol, C. Assenmacher et al. Incidental detection of occult thyroid carcinoma with 11C-choline PET/CT for high risk prostate cancer. Curr. Urol. 10, 217–220 (2016)CrossRef
14.
Zurück zum Zitat N.T.K. Thanseer, S.K. Bhadada, A. Sood, A.S. Parihar, D. Dahiya, P. Singh et al. Dual pathologies of parathyroid adenoma and papillary thyroid cancer on fluorocholine and fluorodeoxyglucose PET/CT. Nucl. Med. Mol. Imaging 52, 154–158 (2018)CrossRefPubMed N.T.K. Thanseer, S.K. Bhadada, A. Sood, A.S. Parihar, D. Dahiya, P. Singh et al. Dual pathologies of parathyroid adenoma and papillary thyroid cancer on fluorocholine and fluorodeoxyglucose PET/CT. Nucl. Med. Mol. Imaging 52, 154–158 (2018)CrossRefPubMed
16.
Zurück zum Zitat M. Beheshti, A. Haroon, J.B. Bomanji, W. Langsteger, Fluorocholine PET/computed tomography. Physiologic uptake, bening findings, and pitfalls. Pet. Clin. 9, 299–306 (2014)CrossRefPubMed M. Beheshti, A. Haroon, J.B. Bomanji, W. Langsteger, Fluorocholine PET/computed tomography. Physiologic uptake, bening findings, and pitfalls. Pet. Clin. 9, 299–306 (2014)CrossRefPubMed
17.
Zurück zum Zitat A. Haroon, L. Zanoni, M. Celli, R. Zakavi, M. Beheshti, W. Langsteger et al. Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients: physiological distribution, statistical differences, imaging pearls, and normal variants. Nucl. Med Comm. 36, 1065–1075 (2015)CrossRef A. Haroon, L. Zanoni, M. Celli, R. Zakavi, M. Beheshti, W. Langsteger et al. Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients: physiological distribution, statistical differences, imaging pearls, and normal variants. Nucl. Med Comm. 36, 1065–1075 (2015)CrossRef
18.
Zurück zum Zitat N. Khan, N. Oriuchi, H. Ninomiya, T. Higuchi, H. Kamada, K. Endo, Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET. Ann. Nucl. Med. 18, 409–417 (2004)CrossRefPubMed N. Khan, N. Oriuchi, H. Ninomiya, T. Higuchi, H. Kamada, K. Endo, Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET. Ann. Nucl. Med. 18, 409–417 (2004)CrossRefPubMed
19.
Zurück zum Zitat T. Torizuka, T. Kanno, M. Futatsubashi, H. Okada, E. Yoshikawa, F. Nakamura et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. J. Nucl. Med. 44, 1051–1056 (2003)PubMed T. Torizuka, T. Kanno, M. Futatsubashi, H. Okada, E. Yoshikawa, F. Nakamura et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. J. Nucl. Med. 44, 1051–1056 (2003)PubMed
20.
Zurück zum Zitat T. Yanagawa, H. Watanabe, T. Inoue, A.R. Ahmed, K. Tomiyoshi, T. Shinozaki et al. Carbon-11 choline positron emission tomography in musculoskeletal tumours: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography. J. Comput. Assist. Tomogr. 27, 175–182 (2003)CrossRefPubMed T. Yanagawa, H. Watanabe, T. Inoue, A.R. Ahmed, K. Tomiyoshi, T. Shinozaki et al. Carbon-11 choline positron emission tomography in musculoskeletal tumours: comparison with fluorine-18 fluorodeoxyglucose positron emission tomography. J. Comput. Assist. Tomogr. 27, 175–182 (2003)CrossRefPubMed
21.
Zurück zum Zitat A. Piccardo, P. Trimboli, M. Rutigliani, M. Puntoni, L. Foppiani, L. Bacigalupo et al. Additional value of integrated 18F-choline PET/4D contrast-enhanced CT in the localization of hyperfunctioning parathyroid glands and correlation with molecular profile. Eur J Nucl Med Mol Imaging (2018). https://doi.org/10.1007/s00259-018-4147-4 A. Piccardo, P. Trimboli, M. Rutigliani, M. Puntoni, L. Foppiani, L. Bacigalupo et al. Additional value of integrated 18F-choline PET/4D contrast-enhanced CT in the localization of hyperfunctioning parathyroid glands and correlation with molecular profile. Eur J Nucl Med Mol Imaging (2018). https://​doi.​org/​10.​1007/​s00259-018-4147-4
23.
Zurück zum Zitat C. Welle, E.L. Cullen, P.J. Peller, V.J. Lowe, R.C. Murphy, G.B. Johnson et al. 11C-choline PET/CT in recurrent prostate cancer and nonprostatic neoplastic processes. Radiographics 36, 279–292 (2016)CrossRefPubMed C. Welle, E.L. Cullen, P.J. Peller, V.J. Lowe, R.C. Murphy, G.B. Johnson et al. 11C-choline PET/CT in recurrent prostate cancer and nonprostatic neoplastic processes. Radiographics 36, 279–292 (2016)CrossRefPubMed
24.
Zurück zum Zitat O. Schillaci, F. Calabria, M. Tavolozza, C. Cicciò, M. Carlani, C.R. Caracciolo et al. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl. Med. Commun. 31, 39–45 (2010)CrossRefPubMed O. Schillaci, F. Calabria, M. Tavolozza, C. Cicciò, M. Carlani, C.R. Caracciolo et al. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl. Med. Commun. 31, 39–45 (2010)CrossRefPubMed
25.
Zurück zum Zitat A. Piccardo, M. Massollo, R. Bandelloni, A. Arlandini, L. Foppiani, Lymph node metastasis from tall-cell thyroid cancer negative on 18F-FDG PET/CT and detected by 18F-choline PET/CT. Clin. Nucl. Med. 40, e417–e419 (2015)CrossRefPubMed A. Piccardo, M. Massollo, R. Bandelloni, A. Arlandini, L. Foppiani, Lymph node metastasis from tall-cell thyroid cancer negative on 18F-FDG PET/CT and detected by 18F-choline PET/CT. Clin. Nucl. Med. 40, e417–e419 (2015)CrossRefPubMed
26.
Zurück zum Zitat J. Jin, C.R. McHenry, Thyroid incidentaloma. Best. Pract. Res. Clin. Endocrinol. Metab. 26, 83–96 (2012)CrossRefPubMed J. Jin, C.R. McHenry, Thyroid incidentaloma. Best. Pract. Res. Clin. Endocrinol. Metab. 26, 83–96 (2012)CrossRefPubMed
27.
Zurück zum Zitat F. Bertagna, G. Treglia, A. Piccardo, R. Giubbini, Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J. Clin. Endocrinol. Metab. 97, 3866–3875 (2012)CrossRefPubMed F. Bertagna, G. Treglia, A. Piccardo, R. Giubbini, Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J. Clin. Endocrinol. Metab. 97, 3866–3875 (2012)CrossRefPubMed
Metadaten
Titel
18F-choline PET/CT incidental thyroid uptake in patients studied for prostate cancer
verfasst von
Domenico Albano
Rexhep Durmo
Francesco Bertagna
Raffaele Giubbini
Publikationsdatum
29.12.2018
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-01832-6

Weitere Artikel der Ausgabe 3/2019

Endocrine 3/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.